Comparative Pharmacology
Head-to-head clinical analysis: BIPHETAMINE 12 5 versus BIPHETAMINE 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIPHETAMINE 12 5 versus BIPHETAMINE 20.
BIPHETAMINE 12.5 vs BIPHETAMINE 20
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Biphetamine 12.5 is a central nervous system stimulant that increases the levels of norepinephrine and dopamine in the synaptic cleft by inhibiting the reuptake of these neurotransmitters and by promoting their release from presynaptic terminals.
Biphetamine 20 is a fixed-dose combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, and inhibit their reuptake, thereby increasing synaptic concentrations of these neurotransmitters in the central nervous system.
12.5 mg orally once daily in the morning, may titrate weekly by 12.5 mg to maximum 75 mg/day.
10-20 mg orally once daily in the morning; may increase to 20 mg twice daily (morning and noon) if needed.
None Documented
None Documented
9-14 hours in children and adolescents; clinical effects typically last 4-6 hours due to distribution and tolerance. Terminal half-life may be longer in adults with higher body fat (up to 20 hours).
0.5–1.5 hours for the immediate-release component; terminal elimination half-life of the total amphetamine salts is approximately 10–13 hours in adults
Renal: 70-80% as unchanged drug and metabolites (primarily deaminated metabolites); fecaroute is negligible. Urinary pH-dependent: acidification increases renal clearance, alkalinization decreases it.
Renal (90% as unchanged drug and metabolites, with approximately 30% unchanged); fecal (10%)
Category C
Category C
Central Nervous System Stimulant
Central Nervous System Stimulant